Neoadjuvant - Adjuvant durvalumab in patients with gastric cancer

• Research type

  Research Study

• Full title

  A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN)

• IRAS ID

  1003436

• Contact name

  Elizabeth Smyth

• Contact email

  Elizabeth.smyth2@nhs.net

• Eudract number

  2019-001555-40

• Clinicaltrials.gov Identifier

  NCT04592913

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  20/SC/0365

• Date of REC Opinion

  13 Nov 2020

• REC opinion

  Further Information Favourable Opinion